Erlotinib Enrolling by Invitation Phase 3 Trials for EGFR Gene Mutations Treatment

IndicationsStatusPurposePhase
Enrolling by InvitationTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02886195EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC